605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II

MYC GSPT1 protein degradation in refractory relapsed T cell prolymphocytic leukemias

Harnessing BCL2 inhibition with BTK inhibition in follicular lymphoma A translational trial with mechanistic insights from single cell analysis

Pre clinical evaluation of surovatamig AZD0486 in comparison to CD20xCD3 bispecific antibodies

Epigenetic targeting of SETD8 in multiple myeloma

ST6GALNAC4 promotes DLBCL progression by regulating ldha sialylation to enhance glycolysis and lactate production

Polatuzumab vedotin induced activation of B cell receptor signaling creates a synthetic lethality with BTK and AKT inhibition in Mantle Cell Lymphoma

Expression of the cancer testis antigen PRAME is associated with response to immune checkpoint inhibitor and rituximab priming in treatment naïve diffuse large B cell lymphoma

BCL 2 inhibition in North American adult T cell leukemia lymphoma Preclinical insights and early clinical outcomes

Identification of ferroptosis sensitizers for DLBCL treatment

Lbl 076 a first in class GPRC5DxCD38xCD3 trispecific T cell engager TCE for the treatment of relapsed refractory multiple myeloma

Dose and BTK occupancy relationship in the prospective Phase 2 TAILOR study Exploratory end point analysis of the ibrutinib monotherapy cohorts in patients with previously untreated chronic lymphocytic leukemia

Overcoming resistance to bispecific antibodies through epigenetic priming in B cell lymphoma

AZD4512 A novel CD22 directed antibody drug conjugate for the treatment of b cell malignancies